Methergine

(Methylergonovine)

Phase 1Small molecule

EEdison Pharmaceuticals Inc

Methergine is one of 36 small molecule programs targeting Cesarean Section. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Cesarean SectionActive, not recruiting

Cesarean SectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

230 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Preclinical

21 2

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

12 3

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

11 4

Proamatine

Takeda

Preclinical

1 5

Duragesic

CCephalon

Preclinical

6 6

Catapres

Boehringer Ingelheim

Preclinical

4 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

4 8

Nubain

AAultman Health Foundation

Preclinical

3 9

Ancef

BBaxter Healthcare Corporation

Preclinical

3 10

Neurontin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cesarean Section2 trials

Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients

Completed·CCynthia Wong·Phase 4·NCT03904446·160 enrolled

Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections

Withdrawn·JJohns Hopkins University·Phase 1·NCT03303235

Unspecified1 trial

Prophylactic Methylergonovine for Twin Cesarean

Completed·—·Phase 4·NCT05772156·66 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

METHERGINE

NDA NDA006035

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Methylergonovine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methylergonovine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methylergonovine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA006035). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Edison Pharmaceuticals Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEdison Pharmaceuticals Inc

Methergine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cesarean Section2 trials

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News